Alterity Therapeutics Plans Issue of 150 Million Options on ASX

An announcement from Alterity Therapeutics ( (AU:ATH) ) is now available.

Alterity Therapeutics has notified the ASX of a proposed issue of up to 150 million options as part of a placement or similar capital-raising structure. The new options will carry an exercise price of A$0.02 and will expire five years after their date of issue, with the proposed issue date set for June 26, 2026.

The company has applied for the options to be quoted on the ASX in line with the relevant listing rules, indicating its intention to maintain an active presence in public markets. This planned issuance is likely aimed at bolstering Alterity’s capital flexibility and could potentially dilute existing shareholders if the options are exercised, while providing additional funding capacity for its therapeutic development programs.

The most recent analyst rating on (AU:ATH) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Alterity Therapeutics stock, see the AU:ATH Stock Forecast page.

More about Alterity Therapeutics

Alterity Therapeutics Limited is an Australian biotechnology company listed on the ASX under the code ATH. The company operates in the life sciences sector, focusing on the development of therapeutic products, with its funding activities conducted via equity and option issuances in the public capital markets.

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$87M

Find detailed analytics on ATH stock on TipRanks’ Stock Analysis page.